Primaquine-induced haemolysis in females heterozygous for G6PD deficiency

被引:0
作者
Cindy S. Chu
Germana Bancone
François Nosten
Nicholas J. White
Lucio Luzzatto
机构
[1] Mahidol University,Shoklo Malaria Research Unit, Faculty of Tropical Medicine, Mahidol–Oxford Tropical Medicine Research Unit
[2] Mahidol University,Mahidol–Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine
[3] University of Oxford,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine
[4] Muhimbili University of Health and Allied Sciences,Department of Haematology
来源
Malaria Journal | / 17卷
关键词
Malaria; G6PD deficiency; Primaquine; G6PD heterozygous female; Radical cure; Haemolysis; 8-aminoquinoline;
D O I
暂无
中图分类号
学科分类号
摘要
Oxidative agents can cause acute haemolytic anaemia in persons with G6PD deficiency. Understanding the relationship between G6PD genotype and the phenotypic expression of the enzyme deficiency is necessary so that severe haemolysis can be avoided. The patterns of oxidative haemolysis have been well described in G6PD deficient hemizygous males and homozygous females; and haemolysis in the proportionally more numerous heterozygous females has been documented mainly following consumption of fava beans and more recently dapsone. It has long been known that 8-aminoquinolines, notably primaquine and tafenoquine, cause acute haemolysis in G6PD deficiency. To support wider use of primaquine in Plasmodium vivax elimination, more data are needed on the haemolytic consequences of 8-aminoquinolines in G6PD heterozygous females. Two recent studies (in 2017) have provided precisely such data; and the need has emerged for the development of point of care quantitative testing of G6PD activity. Another priority is exploring alternative 8-aminoquinoline dosing regimens that are practical and improve safety in G6PD deficient individuals.
引用
收藏
相关论文
共 275 条
[1]  
Earle DP(1948)Studies on the chemotherapy of the human malarias. IX. Effect of pamaquine on the blood cells of man J Clin Invest. 27 121-129
[2]  
Bigelow FS(1948)The clinical trial of 18 analogues of pamaquin (plasmochin) in vivax malaria Chesson strain J Clin Invest. 27 34-45
[3]  
Zubrod CG(2014)Spatial and temporal epidemiology of clinical malaria in Cambodia 2004–2013 Malar J. 13 385-1780
[4]  
Kane CA(2012)Relapses contribute significantly to the risk of J Infect Dis 206 1771-1135
[5]  
Alving AS(2013) infection and disease in Papua New Guinean children 1–5 years of age Antimicrob Agents Chemother 57 1128-4133
[6]  
Pullman TN(2011)Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia Malar J. 10 297-21
[7]  
Craige B(2012)Determinants of relapse periodicity in Blood 120 4123-1166
[8]  
Jones R(2004) malaria Haema. 7 17-872
[9]  
Whorton CM(1926)Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone Naturwissenschaften 14 1162-292
[10]  
Eichelberger L(1995)Favism - from the “avoid fava beans” of Pythagoras to the present J Antimicrob Chemother 36 857-485